Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$1.02 - $1.3 $1,608 - $2,050
-1,577 Reduced 84.15%
297 $0
Q4 2023

Feb 13, 2024

SELL
$0.75 - $1.49 $3,637 - $7,226
-4,850 Reduced 72.13%
1,874 $2,000
Q3 2023

Nov 13, 2023

SELL
$1.23 - $2.25 $64,832 - $118,595
-52,709 Reduced 88.69%
6,724 $8,000
Q2 2023

Aug 14, 2023

BUY
$1.24 - $1.92 $73,696 - $114,111
59,433 New
59,433 $102,000
Q3 2021

Nov 12, 2021

SELL
$18.17 - $24.7 $161,931 - $220,126
-8,912 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$20.08 - $29.02 $47,629 - $68,835
-2,372 Reduced 21.02%
8,912 $213,000
Q1 2021

May 14, 2021

BUY
$27.0 - $32.48 $304,668 - $366,504
11,284 New
11,284 $330,000

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $53.9M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.